Intercytex

www.intercytex.net.

Symbol: ICX.L

Currently trading at: 32p DOWN 1.50

Intercytex is an emerging healthcare developer of cell therapy products for the woundcare and aesthetic medicine markets. It is using its proprietary expertise in cell therapy to develop products that harness the innate ability of human cells to regenerate and repair the body.

Intercytex commenced operations in 2000 and has raised over 31 million pounds in four private equity financing rounds. The Company has over 60 employees and is headquartered in Cambridge, with GMP clinical production facilities and research located in Manchester, UK and additional research laboratories in Boston, MA.

Intercytex has two products currently in clinical development: ICX-PRO and ICX-TRC. ICX-PRO is designed to actively stimulate repair in chronic wounds and is currently in Phase III trials. ICX-TRC is a hair regeneration product in Phase I trials. A third product, ICX-SKN, is in preclinical development as a true skin replacement to overcome the need for skin graft procedures. All Intercytex' products are derived from unmodified, normal human cells.

Staff

Nick Higgins BSc, MSc, Chief Executive Officer Nick joined Intercytex as Chief Executive Officer in January 2005 having been a Non-Executive Director of the Company since its foundation and brings over 20 years of experience in commercialising biotechnology products. He was previously Chief Business Officer and a Board Director of Acambis plc (vaccines) which he joined in 1994. He was responsible for all commercial activities including IP management, licensing, corporate development, mergers/acquisitions and sales and marketing. In addition, he played a key role in the Company’s flotation on the London Stock Exchange in 1995.

Paul Kemp BSc, PhD, Founder and Chief Scientific Officer Paul founded Intercytex in 1999 and is its Chief Scientific Officer. He has over 17 years of experience in the commercial development of cell therapy. Prior to founding Intercytex, he was VP Research at Organogenesis Inc (connective tissue research). He is a principal inventor on several patents related to various regenerative medical therapeutics including wound repair stimulant Apligraf®.

Contact details

Articles relating to Intercytex

Cambridge Cluster pharmas tackle treatments for the bald, wrinkly, and overweight

UK Govt awards £1.85m grant to Intercytex, TAP to automate making of hair loss treatment

News briefs: UK email off the mark in customer service; Malaysia seeks to emulate Silicon Fen

Briefs: NextGen raises cash; Xaar Q3 revenues lower than planned

Briefs: Intercytex raises £2.75m; Autonomy helps corporate users with iPhone

CAT, CSR prop up the Silicon Fen Top 20 Index in May

Silicon Fen Top 20, the Cambridge Cluster's own share price index, launched; will measure the collective bottom line

Silicon Fen Top 20 gains 7.4% in February, pushed along by Alizyme but held back by Plasmon

£30 million venture capital pumped into Cambridge Cluster high-tech firms in past 3 months

Silicon Fen innovations that will soon be in a shop near you

Subscribe

 

Corporate profiles

 • genapta

Dr David Richards Chief Scientific Officer

Genapta Limited supplies high performance optical platforms for pharmaceutical screening, DNA sequencing and genomic testing. Using genapta’s patented optical core the systems are capable of screening chemical compounds down to the few molecule regime, sequence DNA, and image two dimensional arrays of

[genapta's profile]

Top20 Index

Currently: 71.78

Business Networking Groups
Follow this link to business networking. It offers discussion groups, secure video conferencing and more.

Create Publisher Site
This Publisher Website ( slot3.siliconfenbusiness.com ) does not exist in Direct-Link-Ads.com. Please create it now.